The aetiopathogenesis of auditory hallucinations in psychosis;Etiopatogenia de las alucinaciones auditivas en las psicosis

Revista de Neurologia

Volumn 43, Issue 5, 2006, Pages 280-286

  Sanjuán, Julio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

5 HTT; Aetiology; Aetiopathogenic model; Auditory hallucinations; CCK AR; FOXP2; Genes; Psychosis

Indexed keywords

CHOLECYSTOKININ A RECEPTOR; DOPAMINE; SEROTONIN TRANSPORTER; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP2 PROTEIN, HUMAN; SEROTONIN RECEPTOR;

ALZHEIMER DISEASE; AUDITORY HALLUCINATION; BRAIN REGION; CULTURAL FACTOR; EMOTION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; ETIOLOGY; GENETIC MODEL; GENETIC SUSCEPTIBILITY; HUMAN; LANGUAGE; LANGUAGE DISABILITY; LIMBIC SYSTEM; NEUROMODULATION; PARKINSON DISEASE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOCIAL ADAPTATION; BRAIN; GENETICS; HALLUCINATION; HISTOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

BRAIN; FORKHEAD TRANSCRIPTION FACTORS; HALLUCINATIONS; HUMANS; PSYCHOTIC DISORDERS; RECEPTOR, CHOLECYSTOKININ A; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 35348917318     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4305.2006270     Document Type: Review

References (65)

1. David AS. The cognitive neuropsychiatry of auditory verbal hallucinations: an overview. Cogn Neuropsychiatry 2004; 31: 107-23.
2. Sanjuán J. Árbol de decisión: alucinaciones. Psiquiatr Aten Primaria 2002; 3: 1-4.
3. González JC, Sanjuán J, Aguilar E, Berenguer V, Leal C. Dimensiones clínicas de las alucinaciones auditivas. Arch Psiquiatría 2003; 3: 231-46.
4. Leudar I, Thomas P. Voices of reason, voices of insanity. Studies of verbal hallucinations. London: Routledge; 2000.
5. Tamburini A, Berrios GE. A theory of hallucinations. Hist Psychiatry 1990; 1: 145-6.
6. Verdoux H, Van Os J. Psychotic symptoms in non-clinical populations and the continuum of psychosis. Schizophr Res 2002; 54: 59-65.
7. Sidgewick H, Johnson A, Myers FW. Report of the census of hallucinations. Proc Soc Phys Res 1894; 26: 259-394.
8. Johns LC, Cannon C, Singleton N, Murray RM, Farrell M, Brugha T, et al. Prevalence and correlates of self-reported psychotic symptoms in the British population. Br J Psychiatry 2004; 185: 298-305.
9. Barret TR, Etheridge JB. Verbal hallucinations in normals. I: People who hear voices. Appl Cogn Psychol 1992; 6: 379-87.
10. Johns LC, Hemsley D, Kuipers EA. Comparison of auditory hallucinations in a psychiatric and non-psychiatric group. Br J Clin Psychol 2002; 41: 81-6.
11. Al-Issa I. Social and cultural aspects of hallucinations. Psychol Bull 1977; 84: 570-87.
12. Zimmermann G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr Res 2005; 77: 1-9.
13. Woodruff PW. Auditory hallucinations: insights and questions from neuroimaging. Cogn Neuropsychiatry 2004; 9: 73-91.
14. González JC, Sanjuán J, Cañete C, Echanove MJ, Leal C. La evaluación de las alucinaciones auditivas: la escala PSYRATS. Actas Esp Psiquiatr 2003; 31: 10-7.
15. García-Martí G, Aguilar EJ, Martí-Bonmatí L, Lull JJ, González JC, Sanjuán J. Auditory hallucinations in schizophrenia. Schizophr Res 2006; 81 (Suppl): 301.
16. Shergill SS, Brammer MJ, Williams SC, Murray RM, McGuire PK. Mapping auditory hallucinations in schizophrenia using functional magnetic resonance imaging. Arch Gen Psychiatry 2000; 57: 1033-8.
17. Gaser C, Nenadic I, Volz HP, Buchel C, Sauer H. Neuroanatomy of 'hearing voices': a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. Cereb Cortex 2004; 1: 91-6.
18. Hubl D, Koenig T, Strik W, Federspiel A, Kreis R, Boesch C, et al. Pathways that make voices: white matter changes in auditory hallucinations. Arch Gen Psychiatry 2004; 61: 658-68.
19. Kubicki M, Westin CF, McCarley RW, Shenton ME. The application of DTI to investigate white matter abnormalities in schizophrenia. Ann N Y Acad Sci 2005; 1064: 134-48.
20. Sanjuán J, Lull JJ, Martí-Bonmatí L, Aguilar EJ, Gadea M, Moratal-Pérez D, et al. Paradigma auditivo emocional. Una nueva técnica para el estudio de la psicosis. Actas Esp Psiquiatr 2005; 33: 383-9.
21. Sanjuán J, Lull JJ, Aguilar EJ, Martí-Bonmatí L, Moratal D, González JC, et al. Emotional words enhance brain activation in auditory hallucinations schizophrenic patients. Psychiatry Res 2006 [in press].
22. Hoffman RE, Boutros NN, Hu S, Berman RM, Krystal JH, Charney DS. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. Lancet 2000; 355: 1073-5.
23. Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, et al. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry 2005; 58: 97-104.
24. McIntosh AM, Semple D, Tasker K, Harrison LK, Owens DG, Johnstone EC, et al. Transcranial magnetic stimulation for auditory hallucinations in schizophrenia. Psychiatry Res 2004; 127: 9-17.
25. Holi MM, Eronen M, Toivonen K, Toivonen P, Marttunen M, Naukkarinen H. Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophr Bull 2004; 30: 429-34.
26. Sanjuán J. En búsqueda de nuevos fenotipos: la vuelta al síntoma. Arch Psiquiatría 2003; 66: 169-72.
27. De Frutos R, Sanjuán J. Genética de la esquizofrenia. In Vallejo J, Leal C, eds. Tratado de psiquiatría. Tomo I. Barcelona: Ars Médica; 2005. p. 917-38.
28. Egan MF, Goldberg TE, Gscheidle T, Weirich M, Rawlings R, Hyde T, et al. Relative risk for cognitive impairments in siblings of patients with schizophrenia. Biol Psychiatry 2001; 5: 98-107.
29. Sanjuán J, Aguilar EJ, De Frutos R. Time for a broad phenotype in schizophrenia? Br J Psychiatry 2006; 188: 190.
30. Rosenthal D, Quinn OW. Quadruplet hallucinations. Phenotypic variations of a schizophrenic genotype. Arch Gen Psychiatry 1977; 34: 817-27.
31. McGuffin P, Farmer AE, Gottesman II, Murray RM, Reveley AM. Twin concordance for operationally defined schizophrenia. Confirmation of familiarity and heritability. Arch Gen Psychiatry 1984 ; 41: 541-5.
32. Cardno AG, Sham, PC, Farmer AE, Murray RM, McGuffin P. Heritability of Schneider's first-rank symptoms. Br J Psychiatry 2002; 180: 35-8.
33. Sanjuán J, Nájera C, De Frutos R, Moltó MD. Genética de las alucinaciones auditivas. Curr Psychiatry Rep (ed. español) 2005; 2: 34-46.
34. Crow TJ. Auditory hallucinations as primary disorders of syntax: an evolutionary theory of the origins of language. Cogn Neuropsychiatry 2004; 9: 125-45.
35. Lai CS, Fisher SE, Hurst JA, Vargha-Khadem F, Monaco AP. A fork-head-domain gene is mutated in a severe speech and language disorder. Nature 2001; 413: 519-23.
36. Watkins KE, Dronkers NF, Vargha-Khadem F. Behavioural analysis of an inherited speech and language disorder: comparison with acquired aphasia. Brain 2002; 125: 452-64.
37. Corballis MC. FOXP2 and the mirror system. Trends Cogn Sci 2004; 8: 95-6.
38. Vargha-Khadem F, Gadian DG, Copp A, Mishkin M. FOXP2 and the neuroanatomy of speech and language. Nat Rev Neurosci 2005; 6: 131-8.
39. Liegeois F, Baldeweg T, Connelly A, Gadian DG, Mishkin M, Vargha-Khadem F. Language fMRI abnormalities associated with FOXP2 gene mutation. Nat Neurosci 2003; 6: 1230-7.
40. Shu W, Cho JY, Jiang Y, Zhang M, Weisz D, Elder GA, et al. Altered ultrasonic vocalization in mice with a disruption in the FOXP2 gene. Proc Natl Acad Sci USA 2005; 102: 9643-8.
41. Bhati MT. The brain, language, and schizophrenia. Curr Psychiatry Rep 2005; 7: 297-303.
42. Sanjuán J, Tolosa A, González JC, Aguilar EJ, Moltó MD, Nájera C, et al. FOXP2 polymorphisms in patients with schizophrenia. Schizophr Res 2005; 73: 253-6.
43. Sanjuán J, Tolosa A, González JC, Aguilar EJ, Moltó MD, Nájera C, et al. Association between FOXP2 polymorphisms and schizophrenia with auditory hallucinations. Psychiatr Genet 2006; 16: 67-72.
44. Gong X, Jia M, Ruan Y, Shuang M, Liu J, Wu S, et al. Association between the FOXP2 gene and autistic disorder in Chinese population. Am J Med Genet B Neuropsychiatr Genet 2004; 127: 113-6.
45. Kapur S. How antipsychotics become anti-'psychotic' - from dopamine to salience to psychosis. Trends Pharmacol Sci 2004; 25: 402-6.
46. Goetz CG, Burke PF, Leurgans S, Berry-Kravis E, Blasucci LM, Raman R, et al. Genetic variation analysis in Parkinson disease patients with and without hallucinations: case-control study. Arch Neurol 2001; 58: 209-13.
47. Wang J, Zhao CH, Chen B. Polymorphisms of dopamine receptor and transporter genes and hallucinations in Parkinson's disease. Neurosci Lett 2004; 355: 193-6.
48. Toirac I, González JC, Pajuelo JC, Nájera C, Moltó MD, De Frutos R, et al. A pharmacogenetic report on antipsychotic response in patients with auditory hallucinations. Int J Neuropharmacol 2002; Suppl 1: 111.
49. Noble F, Wank SA, Crawley JN, Bradwejn J, Seroogy KB, Hamon M, et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999; 51: 745-81.
50. Rehfeld JF. Cholecystokinin and panic disorder -three unsettled questions. Regul Pept 2000; 93: 79-83.
51. Wei J, Hemmings GP. The CCK-A receptor gene possibly associated with auditory hallucinations in schizophrenia. Eur Psychiatry 1999; 14: 67-70.
52. Tachikawa H, Harada S, Kawanishi Y, Okubo T, Suzuki T. Linked polymorphisms (-333G>T and -286A>G) in the promoter region of the CCK-A receptor gene may be associated with schizophrenia. Psychiatry Res 2001; 103: 147-55.
53. Sanjuán J, Toirac I, González JC, Nájera C, Moltó MD, Leal C, et al. A possible association between the CCK-AR gene and persistent auditory hallucinations in schizophrenia. Eur Psychiatry 2004; 19: 349-53.
54. Lesch KP. Molecular biology, pharmacology, and genetics of the serotonin transporter: psychobiological and clinical implications. In Baumgarten HG, Guthert M, eds. Serotonergic neurons and 5-HT receptors in the CNS. Berlin: Springer; 1997. p. 671-705.
55. 2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease. Hum Mol Genet 1998; 7: 1507-9.
56. Nacmias B, Tedde A, Forleo P, Piacentini S, Guarnieri BM, Bartoli A, et al. Association between 5-HT(2A) receptor polymorphism and psychotic symptoms in Alzheimer's disease. Biol Psychiatry 2001; 50: 472-5.
57. Malhotra AK, Goldman D, Mazzanti C, Clifton A, Breier A, Pickar D. A functional serotonin transporter (5-HTT) polymorphism is associated with psychosis in neuroleptic-free schizophrenics. Mol Psychiatry 1998; 3: 328-32.
58. Golimbet VE, Alfimova MV, Shchebatykh TV, Abramova LI, Kaleda VG, Rogaev EI. Serotonin transporter polymorphism and depressive-related symptoms in schizophrenia. Am J Med Genet 2004; 126: 1-7.
59. Lesch KP. Hallucinations: psychopathology meets functional genomics. Mol Psychiatry 1998; 3: 278-81.
60. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386-9.
61. Sanjuán, J, Rivero O, Aguilar EJ, González JC, Moltó MD, De Frutos R, et al. Serotonin transporter gene polymorphism (5-HTTLPR) and emotional response to auditory hallucinations in schizophrenia. Int J Neuropsychopharmacol 2005; 9: 131-3.
62. Fujii C, Harada S, Ohkoshi N, Hayashi A, Yoshizawa K, Ishizuka C, et al. Association between polymorphism of the cholecystokinin gene and idiopathic Parkinson's disease. Clin Genet 1999; 56: 394-9.
63. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol 2004; 61: 1280-4.
64. Okubo T, Harada S. Polymorphisms of the CCK, CCKAR and CCKBR genes: an association with alcoholism study. J Stud Alcohol 2001; 62: 413-21.
65. Limosin F, Loze JY, Boni CL, Fedeli LP, Hamon M, Rouillon F, et al. The A9 allele of the dopamine transporter gene increases the risk of visual hallucinations during alcohol withdrawal in alcohol-dependent women. Neurosci Lett 2004; 362: 91-4.